Monzambani V - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy.

Maurizi N, Nowak A, Gruner C, Namdar M, Schmied C, Porretta AP, Barbey G, Monzambani V, Monney P, Barbey F. Maurizi N, et al. Among authors: monzambani v. Heart. 2024 Jul 10;110(15):997-1004. doi: 10.1136/heartjnl-2024-323975. Heart. 2024. PMID: 38749654

Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.

Nowak A, Dormond O, Monzambani V, Huynh-Do U, Barbey F. Nowak A, et al. Among authors: monzambani v. Mol Genet Metab. 2022 Sep-Oct;137(1-2):173-178. doi: 10.1016/j.ymgme.2022.08.003. Epub 2022 Aug 23. Mol Genet Metab. 2022. PMID: 36087505 Free article.

[Isolated left ventricular hypertrophy : is it a Fabry disease?].

Barbey F, Dormond O, Monzambani V, Barbey G, Namdar M, Monney P. Barbey F, et al. Among authors: monzambani v. Rev Med Suisse. 2020 Oct 7;16(709):1886-1890. Rev Med Suisse. 2020. PMID: 33026733 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters